ReviewBiomedicines2020
Application of 3D Bioprinting Technologies to the Management and Treatment of Diabetic Foot Ulcers.
Review in Biomedicines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Application of 3D printing in the treatment of diabetic foot ulcers: current status and new insights.Frontiers in bioengineering and biotechnology · 2024Pooled it
- Bioprinting in Tissue Repair and Its ENT Applications.Polymers · 2026Review
- Three-dimensional bioprinted hydrogels for the management of diabetic wounds: A review.BioImpacts : BI · 2026Review
- LETM2 regulates mitochondrial function and autophagy in diabetic foot ulcers: implications for oxidative stress and therapeutic targeting.Functional & integrative genomics · 2025Article
- Cell migration in diabetic wound healing: Molecular mechanisms and therapeutic strategies (Review).International journal of molecular medicine · 2025Review
- Innovative approaches to treatment of eye diseases: advances in stem cell therapy use in ophthalmology.International ophthalmology · 2025Review
- New Perspectives of Hydrogels in Chronic Wound Management.Molecules (Basel, Switzerland) · 2025Review
- Harnessing Bioprinting Technologies for Diabetic Wound Regeneration.Current pharmaceutical biotechnology · 2025Review
- Innovations in hydrogel therapies for diabetic wound healing: bridging the gap between pathophysiology and clinical application.Burns & trauma · 2025Review
- Microenvironment of diabetic foot ulcers: Implications for healing and therapeutic strategies.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Review
- Tissue Bioprinting: Promise and Challenges.Bioengineering (Basel, Switzerland) · 2023Article
- A Berberine-LoadedInternational journal of molecular sciences · 2023Article
- Performance of hybrid gelatin-PVA bioinks integrated with genipin through extrusion-based 3D bioprinting: AnInternational journal of bioprinting · 2023Article
- Research progress and challenges of bioprinting in wound dressing and healing: Bibliometrics-based analysis and perspectives.International journal of bioprinting · 2023Review
- Review
- Wound-Microenvironment Engineering through Advanced-Dressing Bioprinting.International journal of molecular sciences · 2022Article
- Efficiency of Multifunctional Antibacterial Hydrogels for Chronic Wound Healing in Diabetes: A Comprehensive Review.International journal of nanomedicine · 2022Review
- Cellular Interaction of Human Skin Cells towards Natural Bioink via 3D-Bioprinting Technologies for Chronic Wound: A Comprehensive Review.International journal of molecular sciences · 2022Review
- Innovative Cell and Platelet Rich Plasma Therapies for Diabetic Foot Ulcer Treatment: The Allogeneic Approach.Frontiers in bioengineering and biotechnology · 2022Review
- Dual-functional hybrid quaternized chitosan/Mg/alginate dressing with antibacterial and angiogenic potential for diabetic wound healing.Journal of orthopaedic translation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
Diabetes mellitus (DM) is a chronic metabolic disease with increasing prevalence worldwide. Diabetic foot ulcers (DFUs) are a serious complication of DM. It is estimated that 15-25% of DM patients develop DFU at least once in their lifetime. The lack of effective wound dressings and targeted therapy for DFUs often results in prolonged hospitalization and amputations. As the incidence of DM is projected to rise, the demand for specialized DFU wound management will continue to increase. Hence, it is of great interest to improve and develop effective DFU-specific wound dressings and therapies. In the last decade, 3D bioprinting technology has made a great contribution to the healthcare sector, with the development of personalized prosthetics, implants, and bioengineered tissues. In this review, we discuss the challenges faced in DFU wound management and how 3D bioprinting technology can be applied to advance current treatment methods, such as biomanufacturing of composite 3D human skin substitutes for skin grafting and the development of DFU-appropriate wound dressings. Future co-development of 3D bioprinting technologies with novel treatment approaches to mitigate DFU-specific pathophysiological challenges will be key to limiting the healthcare burden associated with the increasing prevalence of DM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.